FDA allows emergency use of Roche’s Actemra for Covid-19
The indication is for intravenous use of the drug in both adult and paediatric patients aged two years and above who are on systemic corticosteroids and need supplemental
Vividion Therapeutics has announced plans to broaden its capabilities with the establishment of a new research and development (R&D) centre and corporate headquarters at San Diego in California, US.
Arrowhead Pharmaceuticals has signed a global collaboration and license agreement with Horizon Therapeutics for the development of RNA interference (RNAi) therapeutic, ARO-XDH. ARO-XDH is a discovery-stage investigational RNAi